Published on September 20th, 2024
HEART OF INNOVATION: INSIDE EDWARDS LIFESCIENCES'
JOURNEY TO TRANSFORM PATIENT CARE
Join us for an unprecedented look into the beating heart of Orange County's largest public company—A global leader that converts compassion and passion into cutting-edge technology and exceptional shareholder value.
Event includes a fireside chat with CFO Scott Ullem (HBS ’89) and Corporate VP Daveen Chopra (HBS ‘07) moderated by Mark Wilser (HBS ’88).
EVENT DETAILS:
Date: Thursday, October 17, 2024
Time: 5:00 PM - 8:00 PM
Agenda: 5:00 to 6:00: Reception and Open House
6:00 to 6:30: Edwards Overview by Scott Ullem
6:30 to 6:45: TMTT Overview by Daveen Chopra
6:45 to 7:00: Edwards Financial Overview by CFO Scott Ullem (HBS '89)
7:00 to 7:25: Fireside Chat with Scott Ullem and Corp. VP Daveen Chopra (HBS '07)
7:25 to 7:30: Patient Video and Closing Remarks
7:30 to 8:00: Optional Post-Evening Mingling
Location: Edwards Lifesciences
One Edwards Way
Irvine, CA 92614
Cost: $30—Member Pre-Registered Online
$50—Non-Member Pre-Registered Online
$60—At the Door (Subject to Availability)
Free—Crimson Circle Members
WHY EDWARD LIFESCIENCES STANDS OUT:
From $1B to $40B: Witness the incredible journey of a company that has grown 40-fold since its spin-off in 2000, driven by a relentless focus on patient outcomes and innovation.
Lives Saved, Value Created: Learn how Edwards' unwavering commitment to improving patient lives has translated into market leadership and extraordinary financial success.
Culture of Innovation: Discover how a mission-driven culture that values every employee has become the catalyst for groundbreaking medical advancements.
Vision Meets Execution: Explore the perfect synergy of strategic foresight and flawless operational execution that has positioned Edwards at the forefront of cardiovascular care.
WHO IS EDWARD LIFESCIENCES?
"Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence, and partnerships with clinicians and healthcare stakeholders, our employees are inspired our patient-focused culture to deliver life-changing innovation to those who need them most."
EVENT HIGHLIGHTS:
Exclusive Presentations: Experience an engaging overview from Scott Ullem, showcasing Edwards' journey from a $1B spin-off to a $40B leader in medical innovation. Dive deep into Transcatheter Mitral and Tricuspid Therapies with Daveen Chopra, and learn how Edwards is expanding treatment options for millions of patients globally.
Fireside Chat: Participate in a dynamic discussion moderated by Mark Wilser, where our speakers will share insights on Edwards' unique innovation strategy, their patient-first culture, and how they're shaping the future of cardiovascular care.
Networking Opportunities: Connect with fellow HBS alumni and influential business leaders in Edwards' cutting-edge facilities, designed to foster collaboration and breakthrough thinking.
Campus Access: Visit Edwards’ Museum which showcases some of the company’s history and technologies, and go back in time to visit a tribute to the company’s founder, Miles Lowell Edwards, and his workshop where the early innovation began.
ABOUT OUR SPEAKERS:
Scott Ullem, Chief Financial Officer (HBS '09)
Scott Ullem has been chief financial officer since 2014. He is responsible for leading Edwards’ global finance organization. In addition, Ullem has executive responsibility for the company’s information technology, information security, risk management, indirect sourcing, and corporate services teams. He also led the creation of Edwards’ Social Impact Investment Fund to expand access to capital in underserved communities. Prior to joining Edwards, he served as chief financial officer of Bemis Company Inc., a S&P 500 supplier of packaging and pressure sensitive materials used in leading food, consumer, and healthcare products. Ullem was also the executive leader of one of Bemis' three business segments. Prior to Bemis, Ullem was an investment banker for 17 years, serving as a managing director at Goldman Sachs and later at Bank of America. As an investment banker, Ullem worked with public and private companies in multiple industries on mergers and acquisitions as well as equity and debt financing. Ullem currently serves on the board of directors of Illumina as well as Berry Global. He is a Henry Crown Fellow at the Aspen Institute. Ullem received his bachelor's degree in political science from DePauw University and his master's degree in business administration from Harvard Business School.
Daveen Chopra, Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies (HBS '07)
Daveen Chopra joined Edwards Lifesciences as corporate vice president, Surgical Structural Heart, in May 2018, and assumed leadership of Transcatheter Mitral and Tricuspid Therapies in January 2023. Chopra has broad experience in the medical technology industry, including global leadership in strategy, marketing, commercial operations, research and development, and program management. Prior to joining Edwards, Chopra held various roles with increasing levels of responsibility at Medtronic, plc, from 2005 to 2018, culminating in a global leadership role as vice president and general manager of its aortic franchise. Chopra previously served as vice president of global marketing leading Medtronic’s endovascular therapies business. While in Medtronic’s endovascular therapies business, he served as vice president, U.S. commercial operations, director of program management office, senior business manager for the endovascular and peripheral business in Asia-Pacific, global group product manager for thoracic stent grafts, and international aortic product manager. Prior to Medtronic, Chopra served as an international strategy consultant at The Parthenon Group supporting clients in various industries ranging from education to industrial manufacturing. In 2021, he joined the board of Octane. Chopra earned a dual bachelor’s degree in economics and biology from Duke University, and a masters from Harvard Business School, where he graduated with honors.
ABOUT EDWARDS LIFESCIENCES:
Founded in 1958 by Miles "Lowell" Edwards, a visionary engineer with over 60 patents, Edwards Lifesciences has grown into a global leader in patient-focused innovations for structural heart disease and critical care monitoring. The company's unwavering commitment to improving patient outcomes is evident in their industry-leading R&D investment (15-16% of sales) and their "Every Heartbeat Matters" initiative, which aims to impact the global burden of heart valve disease.
Edwards' Irvine campus, a testament to their commitment to innovation and employee well-being, features state-of-the-art research facilities, collaborative spaces, and sustainable design elements. This environment fosters the creativity and passion that drive Edwards' continued leadership in cardiovascular care.
Space is limited, and, based on our 2017 sold-out event, we expect tickets to go quickly.
Register now to secure your spot!
We welcome you to what promises to be one of HBSAOC's most exceptional events, ever!
HBSAOC SPONSORSHIP ACKNOWLEDGEMENTS:
For More Information, Please Contact:
As Co-Founder of Global Capital Markets, Mark Wilser is a 25-year veteran investment banker with a proven track record of maximizing shareholder value through M&A and Corporate Finance transactions.
Mark Wilser, Principal
Tel (949) 252-4600 x225
About Global Capital
As a middle market investment banking boutique, Global Capital provides mergers and acquisition advisory services, access to corporate debt and equity capital, and strategic advisory services to successful middle market companies. For over twenty five years, our team has offered companies a unique blend of sophisticated financial expertise and access to the global marketplace of buyers, sellers and financiers.
Catalysts for Corporate Finance Worldwide www.GlobalCapitalMarkets.com ©2024 Global Capital Markets, Inc. All Rights Reserved.
Securities offered through GCMI Securities Corp., member FINRA and SIPC, and a subsidiary of Global Capital Markets. Please reference GCMI Securities Corp. and its team at BrokerCheck.FINRA.org
Comentarios